Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

Gabriel C Caponetti; Bhavana J Dave; Anamarija M Perry; Lynette M Smith; Smrati Jain; Paul N Meyer; Martin Bast; Philip J Bierman; Robert G Bociek; Julie M Vose; James O Armitage; Patricia Aoun; Kai Fu; Timothy C Greiner; Wing C Chan; Warren G Sanger; Dennis D Weisenburger

doi:10.3109/10428194.2015.1034699

Back

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

Journal article

Peer reviewed

Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome

Gabriel C Caponetti, Bhavana J Dave, Anamarija M Perry, Lynette M Smith, Smrati Jain, Paul N Meyer, Martin Bast, Philip J Bierman, Robert G Bociek, Julie M Vose, …

Leukemia & lymphoma, Vol.56(11), pp.3082-3089

11/02/2015

DOI: 10.3109/10428194.2015.1034699

PMID: 25827211

View Online

Abstract

In this study, we investigated the significance of MYC, BCL2 and BCL6 gene abnormalities in a cohort of 205 diffuse large B-cell lymphoma (DLBCL) patients studied by conventional and/or fluorescence in situ hybridization cytogenetic analysis. Combining these methods, 172 cases (84%) were classified as MYC-, 17 (8%) were MYC+/BCL2-/BCL6-, and 16 (8%) were double/triple-hit lymphomas (i.e. MYC+/BCL2+, MYC+/BCL6+, or MYC+/BCL2+/BCL6+). We found a significant difference in event-free survival (EFS) among the three groups (p = 0.02), with the double/triple-hit group having the worst EFS. Patients who were MYC+, but BCL2- and BCL6-, had the best EFS. We conclude that patients with MYC+ DLBCL, but without BCL2 or BCL6 abnormalities, do not have a worse outcome when compared to those who are MYC-. However, patients with double/triple-hit DLBCL have a very poor outcome and should be treated with aggressive or novel therapies.

Adult

Aged

Aged, 80 and over

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Biomarkers, Tumor

Chromosome Aberrations

Chromosome Banding

Female

Gene Rearrangement, B-Lymphocyte

Genes, bcl-2

Genes, myc

Humans

In Situ Hybridization, Fluorescence

Lymphoma, Large B-Cell, Diffuse - drug therapy

Lymphoma, Large B-Cell, Diffuse - genetics

Lymphoma, Large B-Cell, Diffuse - mortality

Lymphoma, Large B-Cell, Diffuse - pathology

Male

Middle Aged

Neoplasm Staging

Prognosis

Proto-Oncogene Proteins c-bcl-6 - genetics

Survival Analysis

Treatment Outcome

Young Adult

Details

Title: Subtitle: Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome
Creators: Gabriel C Caponetti - CHI Health Creighton University Medical Center - Bergan Mercy
Bhavana J Dave - University of Nebraska Medical Center
Anamarija M Perry - University of Manitoba
Lynette M Smith - University of Nebraska Medical Center
Smrati Jain - University of Nebraska Medical Center
Paul N Meyer - e Southern Arizona Veterans Administration Health Care , Tucson , AZ
Martin Bast - University of Nebraska Medical Center
Philip J Bierman - University of Nebraska Medical Center
Robert G Bociek - University of Nebraska Medical Center
Julie M Vose - University of Nebraska Medical Center
James O Armitage - University of Nebraska Medical Center
Patricia Aoun - City Of Hope National Medical Center
Kai Fu - University of Nebraska Medical Center
Timothy C Greiner - University of Nebraska Medical Center
Wing C Chan - City Of Hope National Medical Center
Warren G Sanger - University of Nebraska Medical Center
Dennis D Weisenburger - City Of Hope National Medical Center
Resource Type: Journal article
Publication Details: Leukemia & lymphoma, Vol.56(11), pp.3082-3089
DOI: 10.3109/10428194.2015.1034699
PMID: 25827211
ISSN: 1042-8194
eISSN: 1029-2403
Language: English
Date published: 11/02/2015
Academic Unit: Pathology
Record Identifier: 9984823119602771

Metrics

1 Record Views

12 Times Cited - Web of Science

See more details